Ocumension Therapeutics (1477.HK) Earnings Analysis
Ocumension Therapeutics (1477.HK) next reports earnings on 2026-08-20, consensus EPS -0.03464 HKD. Last quarter (2026-03-26) it beat with EPS -0.04452 HKD vs -0.0779 HKD est (+42.8%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -24.15.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 1477.HK next report earnings?
| Next earnings date | 2026-08-20 |
|---|---|
| Consensus EPS estimate | -0.03464 HKD |
| Revenue estimate | 0.55B |
1477.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-26 | -0.04452 HKD | -0.0779 HKD | +42.8% | Beat |
| 2025-08-21 | -0.18629 HKD | -0.1315 HKD | -41.7% | Miss |
| 2025-03-31 | -0.1736 HKD | -0.19158 HKD | +9.4% | Beat |
| 2024-08-12 | -0.24655 HKD | -0.22563 HKD | -9.3% | Miss |
Beat rate: 2/4 (50%) over reported quarters with consensus data.
1477.HK valuation and analyst view
| Trailing P/E | -24.15 |
|---|---|
| Trailing EPS | -0.20025 HKD |
| Price / book | 1.06 |
| Dividend yield | 0.00% |
| Market cap | 4.78B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Ocumension Therapeutics (1477.HK)'s next earnings date?
Ocumension Therapeutics is next scheduled to report on 2026-08-20, with a consensus EPS estimate of -0.03464 HKD and revenue estimate of 0.55B.
Did 1477.HK beat earnings last quarter?
In its 2026-03-26 report, 1477.HK posted EPS of -0.04452 HKD versus a -0.0779 HKD estimate — a beat of 42.8%.
What is 1477.HK's earnings track record?
Over the last 4 reported quarters with consensus data, 1477.HK beat estimates 2 times (50%).
What is 1477.HK's current P/E ratio and EPS?
1477.HK trades at a trailing P/E of -24.15 on trailing EPS of -0.20025104384733775 HKD.
What do analysts rate 1477.HK?
1477.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.